1384984-29-5Relevant articles and documents
Second-generation antibacterial benzimidazole ureas: Discovery of a preclinical candidate with reduced metabolic liability
Grillot, Anne-Laure,Tiran, Arnaud Le,Shannon, Dean,Krueger, Elaine,Liao, Yusheng,Odowd, Hardwin,Tang, Qing,Ronkin, Steve,Wang, Tiansheng,Waal, Nathan,Li, Pan,Lauffer, David,Sizensky, Emmanuelle,Tanoury, Jerry,Perola, Emanuele,Grossman, Trudy H.,Doyle, Tim,Hanzelka, Brian,Jones, Steven,Dixit, Vaishali,Ewing, Nigel,Liao, Shengkai,Boucher, Brian,Jacobs, Marc,Bennani, Youssef,Charifson, Paul S.
, p. 8792 - 8816 (2014)
Compound 3 is a potent aminobenzimidazole urea with broad-spectrum Gram-positive antibacterial activity resulting from dual inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in rodent models of bacterial infec
SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF
-
, (2014/02/15)
The invention relates to solid forms of the Formula (I) wherein X is -PO(OH)2, -PO(OH)O-M+, or -PO(O-)2?2M+,wherein M is a monovalent cation such as Na+, K+, Li+, or NH4+. The invention also provides pharmaceutically acceptable compositions comprising the solid form of he compound and method of using the compositions in the treatment of various disorders.
PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS
-
, (2012/07/28)
The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I) or a pharmaceutically acceptable salts thereof, wherein R is H or F, and each of R3, R4, and R5 are as defined herein. The compounds of formula (I) and pharmaceutical compositions comprising said compounds and salts inhibit bacterial gyrase and/or Topo IV and are useful in treating bacterial infections.